Leisha A Emens1,2, S Lindsey Davis3, Scott C N Oliver4, Christopher H Lieu3, Ashvini Reddy5, Sharon Solomon5, Lingmin He5, Roland Morley6, Marcella Fassò6, Andrea Pirzkall6, Hina Patel6, Carol O'Hear6, Daniela Ferrara6. 1. Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2. now with University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania. 3. University of Colorado Cancer Center, Aurora. 4. University of Colorado Eye Center, University of Colorado School of Medicine, Aurora. 5. Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland. 6. Genentech Inc, South San Francisco, California.
Abstract
Importance: Checkpoint inhibition in cancer immunotherapy related to T-cell-driven mechanisms of action associated with acute macular neuroretinopathy (AMN) and diffuse retinal venulitis, an adverse event not previously described, is reported here. Objective: To describe 2 patients who developed ophthalmologic events after treatment with the programmed death 1 axis inhibitor, atezolizumab. Design, Setting, and Participants: Retrospective review of 2 patients treated with atezolizumab for metastatic breast cancer and colon cancer, respectively, who presented with AMN and diffuse retinal venulitis conducted at 2 tertiary medical centers. Main Outcomes and Measures: Multimodal imaging including near infrared, optical coherence tomography, and fluorescein angiography were used to characterize retinal vascular abnormalities. Results: Based on optical coherence tomography and multimodal imaging findings, the clinical diagnosis of AMN associated with diffuse retinal venulitis was made in these 2 patients receiving atezolizumab. Conclusions and Relevance: While only 2 cases of patients receiving the programmed death ligand 1 inhibitor atezolizumab who experienced AMN and diffuse retinal venulitis are described here, these findings suggest that patients receiving programmed death 1 axis inhibitor therapies may need to be monitored for unexpected immune-related ocular toxicity including abnormalities of the microvasculature and large retinal vessels. Further studies might investigate the potential mechanisms of retinal vascular changes associated with these therapies.
Importance: Checkpoint inhibition in cancer immunotherapy related to T-cell-driven mechanisms of action associated with acute macular neuroretinopathy (AMN) and diffuse retinal venulitis, an adverse event not previously described, is reported here. Objective: To describe 2 patients who developed ophthalmologic events after treatment with the programmed death 1 axis inhibitor, atezolizumab. Design, Setting, and Participants: Retrospective review of 2 patients treated with atezolizumab for metastatic breast cancer and colon cancer, respectively, who presented with AMN and diffuse retinal venulitis conducted at 2 tertiary medical centers. Main Outcomes and Measures: Multimodal imaging including near infrared, optical coherence tomography, and fluorescein angiography were used to characterize retinal vascular abnormalities. Results: Based on optical coherence tomography and multimodal imaging findings, the clinical diagnosis of AMN associated with diffuse retinal venulitis was made in these 2 patients receiving atezolizumab. Conclusions and Relevance: While only 2 cases of patients receiving the programmed death ligand 1 inhibitor atezolizumab who experienced AMN and diffuse retinal venulitis are described here, these findings suggest that patients receiving programmed death 1 axis inhibitor therapies may need to be monitored for unexpected immune-related ocular toxicity including abnormalities of the microvasculature and large retinal vessels. Further studies might investigate the potential mechanisms of retinal vascular changes associated with these therapies.
Authors: Christopher D Conrady; Marissa Larochelle; Paula Pecen; Alan Palestine; Akbar Shakoor; Ajay Singh Journal: Graefes Arch Clin Exp Ophthalmol Date: 2017-10-27 Impact factor: 3.117
Authors: Amani A Fawzi; Rajeev R Pappuru; David Sarraf; Philip Phuc Le; Colin A McCannel; Lucia Sobrin; Debra A Goldstein; Scott Honowitz; Alex C Walsh; Srinivas R Sadda; Lee M Jampol; Dean Eliott Journal: Retina Date: 2012-09 Impact factor: 4.256
Authors: Lijie Zhai; Stefani Spranger; David C Binder; Galina Gritsina; Kristen L Lauing; Francis J Giles; Derek A Wainwright Journal: Clin Cancer Res Date: 2015-10-30 Impact factor: 12.531
Authors: Joshua S Manusow; Leila Khoja; Nataly Pesin; Anthony M Joshua; Efrem D Mandelcorn Journal: J Immunother Cancer Date: 2014-12-16 Impact factor: 13.751